文献速递免疫规划慢病防控与筛查

口服多价治疗性亚单位疫苗免疫小鼠可抵御幽门螺杆菌感染

Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection.
PubMed 文献 · Vaccine · 2020-03-02

研究将幽门螺杆菌抗原NAP、UreA、UreB与大肠埃希菌双突变热不稳定毒素(dmLT)佐剂配制成多价亚单位疫苗,口服免疫幽门螺杆菌感染小鼠模型,免疫后2周和8周胃内细菌定植显著减少,伴血清抗原特异性IgG和黏膜IgA应答增强及Th1/Th17免疫应答诱导。

要点

  • 口服多价亚单位疫苗(NAP、UreA、UreB加dmLT佐剂)免疫感染小鼠后2周和8周胃内细菌定植显著减少。
  • 细菌负荷下降伴随血清抗原特异性IgG应答和黏膜IgA应答显著升高。
  • 口服免疫还诱导Th1/Th17免疫应答,可能与特异性抗体协同清除幽门螺杆菌。

核心结论

  • 该候选疫苗似能克服幽门螺杆菌的免疫逃逸机制,恢复被抑制的Th2免疫应答并诱导强体液免疫应答。
  • 结果为开发优化口服治疗性幽门螺杆菌疫苗奠定基础,该疫苗需提高UreA和UreB免疫原性并提供长期免疫。

研究设计与样本

  • 研究用NAP、UreA、UreB三种幽门螺杆菌抗原与大肠埃希菌dmLT黏膜佐剂配制多价亚单位疫苗候选,在幽门螺杆菌感染小鼠模型中评价免疫原性和治疗效力。

主要发现

  • 感染小鼠口服免疫后2周和8周胃内细菌定植均显著减少。
  • 细菌负荷下降伴随血清抗原特异性IgG应答和黏膜IgA应答显著升高。
  • 口服免疫诱导Th1/Th17免疫应答,可能与特异性抗体协同清除幽门螺杆菌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Helicobacter pylori is a human class I carcinogen and no effective prophylactic or therapeutic H. pylori vaccine has yet been marketed. H. pylori can escape the host immune response, but the precise immune protection mechanisms in humans remain unknown. In this study, we developed a multivalent, subunit H. pylori vaccine candidate by formulating three commonly used H. pylori antigens, neutrophil-activating protein (NAP), urease subunit A (UreA) and subunit B (UreB) with the mucosal adjuvant, a double-mutant heat-labile toxin (dmLT) from Escherichia coli, and evaluated its immunogenicity and therapeutic efficacy in a mouse model of H. pylori infection. We found that oral immunization of H. pylori-infected mice significantly reduced gastric bacterial colonization at both 2 and 8 weeks after immunization. The reduction in bacterial burdens was accompanied with significantly increased serum antigen-specific IgG responses and mucosal IgA responses. Moreover, oral immunization also induced Th1/Th17 immune responses, which may play a synergistic role with the specific antibodies in the elimination of H. pylori. Thus, our vaccine candidate appears able to overcome the immune evasion mechanism of H. pylori, restore the suppression of Th2 immune responses with the induction of a strong humoral immune response. These results lay the foundation for the development of an optimized oral therapeutic H. pylori vaccine with increased immunogenicity of UreA and UreB, as well as providing long-term immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu M, Zhong Y, Chen J, et al. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine. 2020. PMID: 32139315. doi:10.1016/j.vaccine.2020.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。